Amyotrophic Lateral Sclerosis
Conditions
Keywords
fast skeletal troponin activator, tirasemtiv, CK-2017357, double-blind, randomized, placebo-controlled
Brief summary
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
Detailed description
CY 4031 was a multi-national, double-blind, randomized, placebo-controlled, stratified, parallel group study of tirasemtiv in patients with ALS. The study had three phases: an open-label phase (2 weeks), a double-blind, placebo-controlled phase (48 weeks), and a double-blind, placebo-controlled tirasemtiv withdrawal phase (4 weeks). Patients who completed 2 weeks of treatment with open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three dose levels of tirasemtiv (250 mg/day, 375 mg/day, or 500 mg/day). Approximately 600 patients were planned to be enrolled into the open-label treatment phase. Patients taking riluzole at study entry could continue use of riluzole during the study as long as they had been on a stable dose for at least 30 days prior to study screening. In addition, for patients randomized to tirasemtiv, the riluzole dose was reduced to half the approved dose (ie, reduced to 50 mg once daily) because administration of tirasemtiv approximately doubles the exposure to concomitant riluzole. Patients randomized to placebo continued riluzole at 50 mg twice daily. This was accomplished without unmasking the study's blind as follows: 1. All patients on riluzole took their morning 50 mg dose of riluzole from their personal riluzole supply. 2. The sponsor supplied the evening riluzole dose as double-blind study medication, as follows: (a) for patients randomized to placebo, the double-blind, evening riluzole dose was 50 mg of active riluzole; (b) for patients randomized to tirasemtiv, the double-blind, evening riluzole dose was a matching placebo for riluzole.
Interventions
DRUGTirasemtiv
DRUGPlacebo tablets
Sponsors
Cytokinetics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) ≤ 24 months prior to screening * Upright SVC ≥ 70 % of predicted for age, height and sex * Able to swallow tablets without crushing, and in the opinion of the Investigator, is expected to continue to be able to do so during the trial * A caregiver if one is needed * Clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator * Male patients must agree for the duration of the study and 10 weeks after the end of the study to use a condom during sexual intercourse with female partners who are of childbearing potential (i.e., following menarche until post-menopausal if not anatomically and physiologically incapable of becoming pregnant) and to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) or the male patient must agree to abstain from sexual intercourse during and for 10 weeks after the end of the study, unless the male patient has had a vasectomy and confirmed sperm count is zero * Female patients must be post-menopausal (≥ 1 year) or sterilized, or, if of childbearing potential, not be breastfeeding, have a negative pregnancy test, have no intention to become pregnant during the course of the study, and use effective contraceptive drugs or devices while requiring male partner to use a condom for the duration of the study and for 10 weeks after the end of the study * Patients must be either on a stable dose of riluzole 50 mg twice daily for at least 30 days prior to screening or have not taken riluzole for at least 30 days prior to screening and are willing not to begin riluzole use until they complete study drug dosing
Exclusion criteria
* At the time of screening, any use of non-invasive positive pressure ventilation (NIPPV, e.g. continuous positive airway pressure \[CPAP\] or bi-level positive airway pressure \[BiPAP\]) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation * Patients with a diaphragm pacing system (DPS) at study entry or who anticipate DPS placement during the course of the study * BMI of 20.0 kg/m2 or lower * Unwilling or unable to discontinue tizanidine and theophylline-containing medications during study participation * Serum chloride outside the normal reference range * Neurological impairment due to a condition other than ALS, including history of transient ischemic attack within the past year * Presence at screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data, including, but not limited to: 1. Poorly controlled hypertension 2. NYHA Class II or greater congestive heart failure 3. Chronic obstructive pulmonary disease or asthma requiring daily use bronchodilator medications 4. GI disorder that might impair absorption of study drug 5. History of significant liver disease defined by bilirubin \> 2 times the upper limit of normal (ULN) or ALT or AST \> 3 times the ULN on repeat testing 6. Poorly controlled diabetes mellitus 7. History of vertigo within three months of study entry 8. History of syncope without an explainable or treated cause 9. History of untreated intracranial aneurysm or poorly controlled seizure disorder 10. Amputation of a limb 11. Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient's ability to give informed consent and to understand and/or comply with study procedures 12. Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in situ of the cervix, or squamous cell carcinoma of the skin excised with clean margins) diagnosed and treated within the last two years 13. Any other condition, impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study 14. Patient judged to be actively suicidal or a suicide risk by the Investigator * Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is greater, prior to dosing * Prior participation in any form of stem cell therapy for the treatment of ALS * Previously received tirasemtiv in any previous clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) | 24 weeks | SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics \[eg, height, age, sex\], based on Knudson 83 normative values). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment | 48 weeks | A hand-held dynomometer, with a scale of 0 to 300 pounds, was used to measure muscle strength and handgrip strength (bilateral); the muscle groups tested were: elbow flexion (bilateral), wrist extension (bilateral), knee extension (bilateral), and ankle dorsiflexion (bilateral). The muscle strength mega-score was calculated as the average of responses to all tested muscles as well as handgrip strength. The slope of muscle strength mega-score was the change over time (48 weeks) and analyzed using a mixed model that assumed a random slope effect. For this endpoint, negative values indicate a decline in muscle strength over time. |
| Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment | 48 weeks | This endpoint evaluated the time to occurrence of a decline in percent predicted SVC (as measured by spirometry) of ≥ 20 percentage points, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase. Note: The median time to a ≥ 20% decline in percent predicted SVC, onset of respiratory insufficiency, or death was 302 days for the placebo group and 359, 334, and 337 days for the 250 mg, 375 mg, and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint. |
| Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment | 48 weeks | The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: bulbar functions, fine motor tasks, gross motor tasks, and respiratory function. Respiratory function consists of 3 of the 12 questions, which assess dyspnea, orthopnea, and respiratory insufficiency. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The sum of the response to these 3 questions represents the respiratory domain score. The respiratory domain score ranges from 0 to 12, with higher scores reflecting more normal function and lower scores reflecting more impaired function. |
| Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment | 48 weeks | The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function. |
| Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment | 48 weeks | This endpoint evaluated the time to occurrence of mechanical ventilatory assistance (defined as invasive or non-invasive ventilation for at least 2 hours over a 24-hour period for at least 5 consecutive days) or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase. Note: The median time to first use of mechanical ventilatory assistance or death was not estimable for all but the 375 mg tirasemtiv group (with a value of 367 days). As such the number and percent of patients who met the endpoint (ie, had mechanical ventilatory assistance or died) are presented. |
| Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment | 48 weeks | This endpoint evaluated the time to occurrence of a decline in SVC (as measured by spirometry) to ≤ 50% predicted, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase. Note: The median time to a decline in SVC to ≤ 50% predicted, onset of respiratory insufficiency, or death was not estimable for the placebo group or the 375 mg tirasemtiv group. The median time was estimated as 363 and 351 days for the 250 mg and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint. |
Countries
Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, United Kingdom, United States
Participant flow
Recruitment details
Patients with familial or sporadic amyotrophic lateral sclerosis were enrolled at 79 sites in Belgium, Canada, France, Germany, Great Britain, Ireland, Italy, Netherlands, Portugal, Spain, and the United States. The first patient was screened on 03 September 2015 and the last subject completed on 27 September 2017.
Pre-assignment details
All enrolled patients began open-label tirasemtiv (250 mg) in a 2-week lead-in phase. Completed patients were randomized (3:2:2:2) to placebo or tirasemtiv (250, 375, or 500 mg) for 48 weeks of double-blind treatment. After which, patients on tirasemtiv were re-randomized (1:1) to placebo or tirasemtiv (current dose) for a 4-week withdrawal phase.
Participants by arm
| Arm | Count |
|---|---|
| Double-blind, Placebo-controlled: Group 1 - Placebo Day 1 through Week 48: 2 placebo tablets twice daily | 188 |
| Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM | 126 |
| Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM | 125 |
| Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM | 122 |
| Total | 561 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Double-blind, Placebo-controlled Phase | Adverse Event | 0 | 13 | 23 | 43 | 43 | 0 | 0 | 0 |
| Double-blind, Placebo-controlled Phase | Death | 0 | 10 | 6 | 2 | 4 | 0 | 0 | 0 |
| Double-blind, Placebo-controlled Phase | Lost to Follow-up | 0 | 2 | 0 | 2 | 1 | 0 | 0 | 0 |
| Double-blind, Placebo-controlled Phase | Physician Decision | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 |
| Double-blind, Placebo-controlled Phase | Progressive disease | 0 | 13 | 9 | 8 | 14 | 0 | 0 | 0 |
| Double-blind, Placebo-controlled Phase | Protocol Violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Double-blind, Placebo-controlled Phase | Various | 0 | 9 | 4 | 5 | 2 | 0 | 0 | 0 |
| Double-blind, Placebo-controlled Phase | Withdrawal by Subject | 0 | 4 | 3 | 1 | 2 | 0 | 0 | 0 |
| Double-blind, Withdrawal Phase | Adverse Event | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Double-blind, Withdrawal Phase | Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Double-blind, Withdrawal Phase | Progressive disease | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 1 |
| Double-blind, Withdrawal Phase | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Open-label Lead-in Phase | Adverse Event | 176 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Open-label Lead-in Phase | Lost to Follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Open-label Lead-in Phase | Protocol Violation | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Double-blind, Placebo-controlled: Group 1 - Placebo | Total | Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv | Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv | Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv |
|---|---|---|---|---|---|
| Age, Continuous | 55.9 years STANDARD_DEVIATION 10.63 | 56.5 years STANDARD_DEVIATION 10.24 | 56.0 years STANDARD_DEVIATION 10.81 | 57.4 years STANDARD_DEVIATION 9.09 | 57.1 years STANDARD_DEVIATION 10.2 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants | 10 Participants | 4 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 6 Participants | 1 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 3 Participants | 0 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) White | 181 Participants | 541 Participants | 117 Participants | 120 Participants | 123 Participants |
| Riluzole use at baseline | 141 Participants | 422 Participants | 92 Participants | 94 Participants | 95 Participants |
| Sex: Female, Male Female | 65 Participants | 175 Participants | 38 Participants | 42 Participants | 30 Participants |
| Sex: Female, Male Male | 123 Participants | 386 Participants | 84 Participants | 83 Participants | 96 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 744 | 17 / 188 | 8 / 126 | 10 / 126 | 8 / 125 | 5 / 132 | 4 / 103 | 5 / 101 |
| other Total, other adverse events | 640 / 744 | 182 / 188 | 125 / 126 | 125 / 126 | 125 / 125 | 123 / 132 | 100 / 103 | 95 / 101 |
| serious Total, serious adverse events | 11 / 744 | 53 / 188 | 30 / 126 | 30 / 126 | 32 / 125 | 15 / 132 | 15 / 103 | 11 / 101 |
Outcome results
Primary
Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)
SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics \[eg, height, age, sex\], based on Knudson 83 normative values).
Time frame: 24 weeks
Population: The data presented are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Double-blind, Placebo-controlled: Group 1 - Placebo | Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) | -14.354 % predicted | Standard Error 1.227 |
| Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv | Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) | -12.648 % predicted | Standard Error 1.5165 |
| Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv | Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) | -13.742 % predicted | Standard Error 1.6076 |
| Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv | Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) | -13.927 % predicted | Standard Error 1.7213 |
p-value: 0.762595% CI: [-3.359, 4.583]Repeated-measures mixed model
p-value: 0.839495% CI: [-3.711, 4.566]Repeated-measures mixed model
p-value: 0.378295% CI: [-2.089, 5.503]Repeated-measures mixed model
Secondary
Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment
The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: bulbar functions, fine motor tasks, gross motor tasks, and respiratory function. Respiratory function consists of 3 of the 12 questions, which assess dyspnea, orthopnea, and respiratory insufficiency. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The sum of the response to these 3 questions represents the respiratory domain score. The respiratory domain score ranges from 0 to 12, with higher scores reflecting more normal function and lower scores reflecting more impaired function.
Time frame: 48 weeks
Population: The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Double-blind, Placebo-controlled: Group 1 - Placebo | Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment | -2.26 units on a scale | Standard Error 0.258 |
| Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv | Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment | -1.95 units on a scale | Standard Error 0.32 |
| Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv | Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment | -2.41 units on a scale | Standard Error 0.34 |
| Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv | Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment | -2.59 units on a scale | Standard Error 0.355 |
p-value: 0.452195% CI: [-0.5, 1.12]Repeated-measures mixed model
p-value: 0.71295% CI: [-1, 0.68]Repeated-measures mixed model
p-value: 0.45195% CI: [-1.19, 0.53]Repeated-measures mixed model
Secondary
Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment
The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function.
Time frame: 48 weeks
Population: The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Double-blind, Placebo-controlled: Group 1 - Placebo | Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment | -11.39 units on a scale | Standard Error 0.695 |
| Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv | Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment | -11.39 units on a scale | Standard Error 0.859 |
| Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv | Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment | -12.19 units on a scale | Standard Error 0.903 |
| Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv | Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment | -11.99 units on a scale | Standard Error 0.937 |
p-value: 0.999195% CI: [-2.17, 2.17]Repeated-measures mixed model
p-value: 0.480895% CI: [-3.04, 1.43]Repeated-measures mixed model
p-value: 0.608295% CI: [-2.89, 1.69]Repeated-measures mixed model
Secondary
Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment
A hand-held dynomometer, with a scale of 0 to 300 pounds, was used to measure muscle strength and handgrip strength (bilateral); the muscle groups tested were: elbow flexion (bilateral), wrist extension (bilateral), knee extension (bilateral), and ankle dorsiflexion (bilateral). The muscle strength mega-score was calculated as the average of responses to all tested muscles as well as handgrip strength. The slope of muscle strength mega-score was the change over time (48 weeks) and analyzed using a mixed model that assumed a random slope effect. For this endpoint, negative values indicate a decline in muscle strength over time.
Time frame: 48 weeks
Population: The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Double-blind, Placebo-controlled: Group 1 - Placebo | Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment | -0.1501 pounds/day |
| Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv | Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment | -0.1512 pounds/day |
| Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv | Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment | -0.1434 pounds/day |
| Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv | Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment | -0.1413 pounds/day |
p-value: 0.950595% CI: [-0.0374, 0.0351]Repeated-measures mixed model
p-value: 0.733695% CI: [-0.0317, 0.045]Repeated-measures mixed model
p-value: 0.659395% CI: [-0.0303, 0.0479]Repeated-measures mixed model
Secondary
Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment
This endpoint evaluated the time to occurrence of a decline in percent predicted SVC (as measured by spirometry) of ≥ 20 percentage points, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase. Note: The median time to a ≥ 20% decline in percent predicted SVC, onset of respiratory insufficiency, or death was 302 days for the placebo group and 359, 334, and 337 days for the 250 mg, 375 mg, and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.
Time frame: 48 weeks
Population: The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Double-blind, Placebo-controlled: Group 1 - Placebo | Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment | 98 Participants |
| Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv | Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment | 58 Participants |
| Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv | Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment | 58 Participants |
| Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv | Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment | 57 Participants |
p-value: 0.236995% CI: [0.587, 1.141]Regression, Cox
p-value: 0.94295% CI: [0.711, 1.372]Regression, Cox
p-value: 0.685395% CI: [0.668, 1.304]Regression, Cox
Secondary
Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment
This endpoint evaluated the time to occurrence of a decline in SVC (as measured by spirometry) to ≤ 50% predicted, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase. Note: The median time to a decline in SVC to ≤ 50% predicted, onset of respiratory insufficiency, or death was not estimable for the placebo group or the 375 mg tirasemtiv group. The median time was estimated as 363 and 351 days for the 250 mg and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.
Time frame: 48 weeks
Population: The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Double-blind, Placebo-controlled: Group 1 - Placebo | Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment | 57 Participants |
| Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv | Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment | 39 Participants |
| Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv | Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment | 30 Participants |
| Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv | Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment | 32 Participants |
p-value: 0.766795% CI: [0.698, 1.627]Regression, Cox
p-value: 0.661995% CI: [0.577, 1.419]Regression, Cox
p-value: 0.585695% CI: [0.561, 1.386]Regression, Cox
Secondary
Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment
This endpoint evaluated the time to occurrence of mechanical ventilatory assistance (defined as invasive or non-invasive ventilation for at least 2 hours over a 24-hour period for at least 5 consecutive days) or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase. Note: The median time to first use of mechanical ventilatory assistance or death was not estimable for all but the 375 mg tirasemtiv group (with a value of 367 days). As such the number and percent of patients who met the endpoint (ie, had mechanical ventilatory assistance or died) are presented.
Time frame: 48 weeks
Population: The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Double-blind, Placebo-controlled: Group 1 - Placebo | Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment | 60 Participants |
| Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv | Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment | 31 Participants |
| Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv | Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment | 37 Participants |
| Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv | Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment | 33 Participants |
p-value: 0.260295% CI: [0.5, 1.206]Regression, Cox
p-value: 0.674895% CI: [0.72, 1.662]Regression, Cox
p-value: 0.769495% CI: [0.609, 1.443]Regression, Cox